Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Starting zero based budgeting at the right time can enhance your financial management. Discover the best moments to implement this budgeting method.
25,575 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A major investment firm boosted its Dyne Therapeutics stake by nearly $4 million, highlighting renewed interest in DY...
Aave Labs unveiled a multi-layered security framework for its V4 release, backed by a $1.5 million audit program. The...
A new wave of on-chain data shows the majority of XRP in circulation remains underwater, signaling potential selling ...
AVAV is set to report Q3 results after the close. Analysts expect revenue around $203 million and non-GAAP EPS near $...
Campbell’s posts worst quarters as revenue and margins deteriorate across key segments. The company trims full-year t...
Bitcoin surged past $74,000 as institutional buying returned to the market, sparking a wider crypto rally. Investors ...
Lumentum shares jumped about 12% on a $2 billion NVIDIA partnership, as AI data-center buildout and robust backlog un...
New York’s upstart candidate Jack Schlossberg argues JFK would be alarmed by America’s global standing, while acknowl...
FELG has fallen about 8% year-to-date as megacap tech leads a broad pullback in growth stocks. The ETF tracks fidelit...
A sharp 20% plunge in Circle tokens sparked by yield shifts under a new Clarity Act framework. This morning minute re...
As 2026 begins, Tesla faces pressure on deliveries while BYD battles domestic slumps but advances fast charging and o...